放射性标记地曼诺cept经系膜细胞摄取实现肾小球分子成像
本研究在大鼠PET中验证68Ga-IRDye800-tilmanocept经CD206受体介导结合于肾小球系膜细胞,并用99mTc-tilmanocept在糖尿病db/db小鼠中显示肾脏时间-活性曲线随病程呈多相变化,提示该探针可能无创定量评估肾小球功能。
要点
- 68Ga-IRDye800-tilmanocept在大鼠PET中显示受体介导的肾小球摄取,肾皮质活性持续40分钟。
- 免疫荧光证实CD206与探针在肾小球内共定位;共注射未标记tilmanocept及阴性对照的肾小球蓄积显著低于CD206靶向探针。
- db/db糖尿病小鼠肾脏时间-活性曲线呈多相且膀胱蓄积高,非糖尿病db/m小鼠以单相为主且膀胱蓄积低。
核心结论
- 放射性标记tilmanocept经CD206受体介导结合于肾小球系膜细胞。
- tilmanocept的肾脏动力学对慢性肾脏病具有敏感性。
- PET或SPECT肾成像用放射性标记tilmanocept可能无创定量评估肾小球功能。
研究设计与样本
- 大鼠置于PET扫描仪,视野含肝和肾,静脉注射68Ga-IRDye800-tilmanocept后成像20分钟并行全身扫描。
- 大鼠分组:0.02 nmol/g(n=5)、0.10 nmol/g(n=5)、共注射68Ga-IRDye800-tilmanocept(0.10 nmol/g)与未标记tilmanocept(5.0 nmol/g)(n=3)、阴性对照68Ga-IRDye800-DTPA-galactosyl-dextran(0.02 nmol/g,n=5)。
- 糖尿病db/db小鼠(4.9周n=6;7.3周n=4;13.3周n=6)及非糖尿病db/m小鼠(n=6)用荧光标记99mTc-tilmanocept(18.5 MBq,2.6 nmol)行分子成像。
- 冷冻肾切片用免疫荧光染色足细胞和CD206。
主要发现
- 大鼠PET全身图像及68Ga-IRDye800-tilmanocept时间-活性曲线显示受体介导的肾脏蓄积,并有肾小球摄取证据。
- 肾皮质内活性在40分钟研究期间持续存在。
- 组织学检查显示CD206与IRDye800-tilmanocept在肾小球内共定位。
- 共注射及阴性对照研究的肾小球蓄积显著低于CD206靶向探针。
- db/db小鼠肾脏时间-活性曲线呈多相且膀胱蓄积高;非糖尿病小鼠肾脏摄取曲线以单相为主且膀胱蓄积低。
关键数值与推荐
- 大鼠68Ga-IRDye800-tilmanocept剂量为0.02 nmol/g或0.10 nmol/g,共注射未标记tilmanocept为5.0 nmol/g。
- 阴性对照68Ga-IRDye800-DTPA-galactosyl-dextran剂量为0.02 nmol/g。
临床怎么用
- 放射性标记tilmanocept PET或SPECT肾成像可能用于无创定量评估肾小球功能。
- 鉴于系膜细胞在糖尿病肾病进展中的作用,该探针可能有助于慢性肾脏病早期肾小球功能监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An unmet need for the clinical management of chronic kidney disease is a predictive tool of kidney function during the first decade of the disease, when there is silent loss of glomerular function. The objective of this study was to demonstrate receptor-mediated binding of tilmanocept to CD206 within the kidney and provide evidence of kinetic sensitivity of this binding to renal function. Methods: Rats were positioned in a PET scanner with the liver and kidneys within the field of view. After an intravenous injection of 68Ga-IRDye800-tilmanocept, using 1 of 2 scaled molar doses (0.02 nmol/g, n = 5; or 0.10 nmol/g, n = 5), or coinjection (n = 3) of 68Ga-IRDye800-tilmanocept (0.10 nmol/g) and unlabeled tilmanocept (5.0 nmol/g), or a negative control, 68Ga-IRDye800-DTPA-galactosyl-dextran (0.02 nmol/g, n = 5), each animal was imaged for 20 min followed by a whole-body scan. Frozen kidney sections were stained for podocytes and CD206 using immunofluorescence. Molecular imaging of diabetic db/db mice (4.9 wk, n = 6; 7.3 wk, n = 4; 13.3 wk, n = 6) and nondiabetic db/m mice (n = 6) was performed with fluorescence-labeled 99mTc-tilmanocept (18.5 MBq, 2.6 nmol). Thirty minutes after injection, blood, liver, kidneys, and urine were assayed for radioactivity. Renal time-activity curves were generated. Results: Rat PET whole-body images and time-activity curves of 68Ga-IRDye800-tilmanocept demonstrated receptor-mediated renal accumulation with evidence of glomerular uptake. Activity within the renal cortex persisted during the 40-min study. Histologic examination demonstrated colocalization of CD206 and IRDye800-tilmanocept within the glomerulus. The glomerular accumulation of the coinjection and the negative control studies were significantly less than the CD206-targeted agent. The db/db mice displayed a multiphasic renal time-activity curve with high urinary bladder accumulation; the nondiabetic mice exhibited renal uptake curves dominated by a single phase with low bladder accumulation. Conclusion: This study demonstrated receptor-mediated binding to the glomerular mesangial cells and kinetic sensitivity of tilmanocept to chronic renal disease. Given the role of mesangial cells during the progression of diabetic nephropathy, PET or SPECT renal imaging with radiolabeled tilmanocept may provide a noninvasive quantitative assessment of glomerular function.
引用
- Qin Z, Hoh CK, Olson ES, et al. Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept. J Nucl Med. 2019. PMID: 30796169. doi:10.2967/jnumed.118.223727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。